BridgeBio Oncology Therapeutics

(NASDAQ) BBOT

Current Price$8.09

Market Cap$651.32M

Since IPO (2024)-23%

5 YearN/A

1 YearN/A

1 Month-3%

BridgeBio Oncology Therapeutics Financials at a Glance

Market Cap

$651.32M

Revenue (TTM)

$0.00

Net Income (TTM)

$134.04M

EPS (TTM)

$-1.50

P/E Ratio

-5.44

Dividend

$0.00

Beta (Volatility)

2.24 (High)

Dividend

$0.00

Beta (Volatility)

2.24 (High)

Price

$8.09

Volume

5,631

Open

$7.74

Price

$8.09

Volume

5,631

Open

$7.74

Previous Close

$8.09

Daily Range

$7.74 - $8.09

52-Week Range

$7.60 - $14.87

Dividend

$0.00

Beta (Volatility)

2.24 (High)

Price

$8.09

Volume

5,631

Open

$7.74

Previous Close

$8.09

Daily Range

$7.74 - $8.09

52-Week Range

$7.60 - $14.87

BBOT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BridgeBio Oncology Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Eli M. Wallace, PhD

Website

bbotx.com

Headquarters

South San Francisco, CA 94080, US

BBOT Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-28%

Return on Capital

-35%

Return on Assets

-30%

Earnings Yield

-18.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$651.32M

Shares Outstanding

80.11M

Volume

5.63K

Avg. Volume

317.11K

Financials (TTM)

Gross Profit

$610.00K

Operating Income

$145.82M

EBITDA

$145.82M

Operating Cash Flow

$113.89M

Capital Expenditure

$606.00K

Free Cash Flow

$114.50M

Cash & ST Invst.

$425.46M

Total Debt

$2.77M

BridgeBio Oncology Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$194.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$651.32M

N/A

Market Cap/Employee

$10.51M

N/A

Employees

N/A

Net Income

$38.80M

-97.1%

EBITDA

$43.21M

-98.0%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$422.69M

+24796.9%

Accounts Receivable

$386.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.24M

N/A

Short Term Debt

$522.00K

N/A

Return on Assets

-29.90%

N/A

Return on Invested Capital

-35.28%

N/A

Free Cash Flow

$55.55K

+36.8%

Operating Cash Flow

$375.55K

-327.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

XNCRXencor, Inc.

XNCRXencor, Inc.$12.44-2.74%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$12.53+2.54%

SEPNSepterna, Inc.

SEPNSepterna, Inc.$24.84+5.39%

NRIXNurix Therapeutics, Inc.

NRIXNurix Therapeutics, Inc.$15.96-1.97%

URGNUroGen Pharma Ltd.

URGNUroGen Pharma Ltd.$29.80-4.88%

OCSOculis Holding AG

OCSOculis Holding AG$30.41-6.86%

KODKodiak Sciences Inc.

KODKodiak Sciences Inc.$39.49-0.90%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.96-0.05%

NOKNokia

NOKNokia$13.17-0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$74.96-0.03%

WOKWork Medical Technology Group Ltd

WOKWork Medical Technology Group Ltd$6.66+0.70%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.31+0.03%

SOFISoFi Technologies

SOFISoFi Technologies$15.90-0.02%

RXTRackspace Technology

RXTRackspace Technology$6.33+0.35%

Questions About BBOT

What is the current price of BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics is trading at $8.09 per share.

What is the 52-week range for BridgeBio Oncology Therapeutics?

Over the past 52 weeks, BridgeBio Oncology Therapeutics has traded between $7.60 and $14.87.

How much debt does BridgeBio Oncology Therapeutics have?

As of the most recent reporting period, BridgeBio Oncology Therapeutics reported total debt of $2.77M.

How much cash does BridgeBio Oncology Therapeutics have on hand?

BridgeBio Oncology Therapeutics reported $373.69M in cash and cash equivalents in its most recent financial results.

What is BridgeBio Oncology Therapeutics’s dividend yield?

BridgeBio Oncology Therapeutics does not currently have a dividend yield.

BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics Financials at a Glance

BBOT News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About BridgeBio Oncology Therapeutics

BBOT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

BridgeBio Oncology Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BBOT

What is the current price of BridgeBio Oncology Therapeutics?

What is the 52-week range for BridgeBio Oncology Therapeutics?

How much debt does BridgeBio Oncology Therapeutics have?

How much cash does BridgeBio Oncology Therapeutics have on hand?

What is BridgeBio Oncology Therapeutics’s dividend yield?

Premium Investing Services